Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Non-Current Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Other Non-Current Assets data on record, last reported at $1.2 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Assets changed 0.0% to $1.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.2 million, a 0.0% change, with the full-year FY2025 number at $1.2 million, up 11910.0% from a year prior.
  • Other Non-Current Assets reached $1.2 million in Q1 2026 per FULC's latest filing, roughly flat from $1.2 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for FULC hit a ceiling of $2.1 million in Q4 2022 and a floor of $9000.0 in Q3 2025.
  • A 5-year average of $1.1 million and a median of $1.2 million in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: crashed 99.5% in 2024, then surged 11910.0% in 2025.
  • Tracing FULC's Other Non-Current Assets over 5 years: stood at $2.1 million in 2022, then fell by 4.47% to $2.0 million in 2023, then plummeted by 99.5% to $10000.0 in 2024, then soared by 11910.0% to $1.2 million in 2025, then changed by 0.0% to $1.2 million in 2026.
  • Business Quant data shows Other Non-Current Assets for FULC at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $9000.0 in Q3 2025.